Immune cells from the spleen found to control chronic high blood pressure

November 20, 2014

High blood pressure is a leading cause of death around the world, and its prevalence continues to rise. A study published by Cell Press on November 20th in the journal Immunity shows that a protein in the spleen called placental growth factor (PlGF) plays a critical role in activating a harmful immune response that leads to the onset of high blood pressure in mice. The findings pave the way for the development of more effective treatments for this common and deadly condition.

High blood pressure, also known as hypertension, affects more than 1 billion people worldwide and is a major risk factor for stroke, heart failure, and kidney diseases. Mounting evidence suggests that immune cells such as T cells contribute to the development of hypertension, but the underlying mechanisms have not been clear. Senior study author Giuseppe Lembo of IRCCS Neuromed and his team suspected that PlGF could be the missing link because it plays important roles in both the cardiovascular system and the immune system.

The researchers found support for this idea in the new study. Mice that were genetically engineered to lack PlGF did not develop hypertension after they were infused with angiotensin II--a hormone that normally increases blood pressure. These mice were also protected from hypertension-related heart and kidney damage, unlike genetically normal mice. Moreover, PlGF deficiency prevented T cells from leaving the spleen, entering the blood stream, and infiltrating the vessels and kidneys where hypertension was manifested. Additional experiments revealed that the nervous system controls levels of PlGF in the spleen, and PlGF in the spleen in turn is essential for the activation of T cells and the onset of hypertension.

"In recent years, anti-PlGF monoclonal antibodies have been developed as a strategy to slow tumor growth and for age-related macular degeneration," says lead study author Daniela Carnevale. "The ongoing clinical trials testing humanized monoclonal antibodies directed to PlGF opens up the possibility of targeting it in hypertension too."

"There is a pressing need for new treatments to control and better target resistant hypertension," says Lembo. "PlGF is an appealing molecular therapeutic target because clinical tools to target this pathway already exist."
-end-
Immunity, Carnevale et al.: "The angiogenic factor PlGF mediates a neuroimmune interaction in the spleen to allow the onset of hypertension"

Cell Press

Related Hypertension Articles from Brightsurf:

Risk of target organ damage in patients with masked hypertension versus sustained hypertension
In a new publication from Cardiovascular Innovations and Applications; DOI https://doi.org/10.15212/CVIA.2019.1261, Yue Wu, Guoyue Zhang, Rong Hu and Jianlin Du from The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China consider the risk of target organ damage in patients with masked hypertension versus sustained hypertension.

Overactive enzyme causes hereditary hypertension
After more than 40 years, several teams at the MDC and ECRC have now made a breakthrough discovery with the help of two animal models: they have proven that an altered gene encoding the enzyme PDE3A causes an inherited form of high blood pressure.

Diagnosing hypertension in children
Study results call into question the utility of testing blood pressure load--the proportion of elevated blood pressure readings detected over 24 hours--for diagnosing hypertension in children.

When the best treatment for hypertension is to wait
A new study concluded that a physician's decision not to intensify hypertension treatment is often a contextually appropriate choice.

Treatment of hypertension induced albuminuria
Patients with albuminuria will usually need more than one drug to achieve blood pressure control, particularly if the aim is also to reduce albuminuria.

Diagnosing and treating resistant hypertension
Resistant blood pressure affects 12 percent to 15 percent of people currently being treated for high blood pressure.

Dementia can be caused by hypertension
A new study in Cardiovascular Research indicates that patients with high blood pressure are at a higher risk of developing dementia.

Hormone imbalance causes treatment-resistant hypertension
British researchers have discovered a hormone imbalance that explains why it is very difficult to control blood pressure in around 10 per cent of hypertension patients.

Breastfeeding reduces hypertension risk
A study published in the American Journal of Hypertension indicates that women who breastfeed more children, and for longer periods of time, are less likely to suffer from hypertension after they reach menopause.

Lung cancer triggers pulmonary hypertension
Nearly half of all advanced-stage lung cancer patients develop arterial pulmonary hypertension.

Read More: Hypertension News and Hypertension Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.